Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo

This article was originally published here

“Vitiligo is a challenging and life-altering disease further complicated by the lack of effective treatment options available to physicians and their patients,” said Jim Lee, M.D., Ph.D., Group

The post Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply